Developer docs
API playgroundTry for free, no card

Search company profiles

BBI Solutions

Full company profile

uuid0008ykl

Namestring
BBI Solutions
Legal namestring
Baduhenna Topco Limited
Company typeenum
Private
Founded yearint
1986
Descriptiontext

BBI Solutions is a UK-headquartered manufacturer of raw materials, reagents, and contract manufacturing services for the in vitro diagnostics (IVD) and life sciences industries. Founded in 1955 and operating from Crumlin with regional offices in Germany, the United States, China, and South Africa, the company employs over 500 people across seven global facilities. Its product portfolio centers on critical assay components: native and recombinant enzymes (including horseradish peroxidase, where BBI claims the position of world's largest primary manufacturer powering more than 5 billion glucose strips annually), antibodies, antigens, gold colloid and gold conjugates (powering more than 400 million lateral flow tests per year), cell culture reagents such as Holo and Apo transferrin, and human serum controls.

The company's core technology is upstream biochemical manufacturing rather than software or instrumentation. Production capabilities include up to 5,000-liter batch purification, gold nanoparticles with coefficient of variation of 8% or less, and over 600 custom gold conjugations per year, all operated under ISO 13485-certified quality systems with a supply resilience framework that includes inventory coverage and secondary sourcing for strategic products. Beyond catalog reagent sales, BBI operates a meaningful contract manufacturing business spanning antibody development and production, lateral flow device assembly from pilot to multi-million-unit runs, custom gold conjugation, and protein customization with fermentation fine-tuning.

BBI's commercial model is B2B sales-led, targeting IVD manufacturers and life sciences companies through direct enterprise sales, regional offices, an e-commerce storefront, and event marketing at industry conferences such as ADLM and ADA. Pricing is quotation-based, reflecting the customized nature of reagent supply and contract manufacturing agreements. The company is privately held under Baduhenna Topco Limited, has executed multiple acquisitions (including IBEX Technologies for $37.9 million in April 2024), and most recently announced a strategic partnership with Lateral Dx in December 2025 to integrate assay development with manufacturing scale.

Short descriptiontext

BBI Solutions manufactures IVD raw materials and contract manufacturing services — enzymes, antibodies, antigens, gold conjugates, and lateral flow components — for diagnostic OEMs and life sciences companies across five continents.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCrumlin, United Kingdom
HQ citystring
Crumlin
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IVD reagents, diagnostic enzymes, gold nanoparticles, lateral flow assays, antibody manufacturing
Industry4 codes
1Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
CodeHLAGAIAIPrimaryYes
2Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
CodeHLAAAMALPrimaryNo
3Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
CodeHLAAAIABPrimaryNo
4Blood Bank, Transfusion Medicine & Immunohematology
CodeHLAHAAAHPrimaryNo
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
In Vitro Diagnostics (IVD) Reagents
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Reagent Product Sales
TypeOne Time License
Description

Sale of native and recombinant reagents including enzymes, antibodies, antigens, gold colloid, gold conjugates, cell culture reagents, stabilizers, blockers, and substrates to IVD manufacturers

bbisolutions.com
2Contract Manufacturing Services
TypeProfessional Services
Description

ISO 13485-certified manufacturing services including antibody production, lateral flow contract manufacture, and custom gold conjugation

bbisolutions.com
3Custom Development
TypeProfessional Services
Description

Tailored reagent customization including bespoke antigens, high-activity enzymes, protein customization, and custom conjugations

bbisolutions.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1B2B reagent sales with quotation-based pricing
ModelOther
Notes

Pricing determined through direct consultation with sales team based on volume, specifications, and customization requirements

bbisolutions.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BBI Solutions manufactures and supplies native and recombinant reagents for the in vitro diagnostics industry, including enzymes (notably Horseradish Peroxidase), antibodies, antigens, gold colloid, gold conjugates, cell culture reagents, human serum and control materials, immuno-affinity columns, polystreptavidin, stabilizers/blockers/substrates, and ELISA kits. The company complements its catalog with ISO 13485-certified contract manufacturing services covering antibody development and production, lateral flow device assembly, custom gold conjugation, and protein customization for diagnostic test developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 5bn+ annual glucose strips powered by BBI enzymes
+4 more records
Product overview1 text field

BBI Solutions is a provider of world-class reagents and IVD manufacturing services for the diagnostics and life sciences industries. The product portfolio centers on critical raw materials for diagnostic assay development: native and recombinant enzymes (including HRP, where BBI is the world's largest primary manufacturer powering over 5 billion annual glucose strips), antibodies and antigens across clinical areas (autoimmune, cardiac, infectious disease, diabetes, hormones, tumor markers), gold colloid and gold conjugates for lateral flow detection (powering 400+ million annual tests), cell culture reagents including transferrin products, and human serum control materials. The company complements its reagent catalog with contract manufacturing services including antibody development and production, lateral flow contract manufacture, custom gold conjugation (600+ annually), and protein customization. The portfolio is organized as catalog reagents plus customization services, supporting customers from discovery through commercial-scale production under ISO 13485 certification.

Product and service17 records
1Enzymes
CategoryIVD Reagents
Description

Enzymes used as critical reagents in diagnostic testing, including Horseradish Peroxidase (HRP) where BBI is the world's largest primary manufacturer. Enzymes support applications such as glucose monitoring and lateral flow tests for IVD manufacturers.

2Antibodies
CategoryIVD Reagents
Description

Antibodies for diagnostic assay development, including secondary antibodies and controls, used in IVD applications across autoimmune, inflammation, cardiac, and infectious diseases clinical areas.

3Gold Colloid
CategoryIVD Reagents
Description

Gold colloid nanoparticles used as detection reagents in lateral flow diagnostics, with BBI's gold colloid powering over 400 million lateral flow tests annually.

4Gold Conjugates
CategoryIVD Reagents
Description

Gold conjugate reagents linking antibodies, antigens, or oligos to ultra-uniform gold nanoparticles (≤8% CV) for lateral flow assay detection, with custom conjugation services available.

5Antigens
CategoryIVD Reagents
Description

Antigens used as capture and detection reagents in immunoassays, covering clinical areas including infectious disease, tumor markers, hormones, and autoimmune conditions.

6Cell Culture Reagents
CategoryLife Sciences Reagents
Description

Cell culture reagents including Holo and Apo transferrin products manufactured under ISO 13485 certification from FDA-licensed plasma, used to accelerate cell growth in serum-free cultures.

7Human Serum & Control Materials
CategoryIVD Reagents
Description

Human serum and control materials used as reference standards and quality controls in diagnostic assay development and manufacturing.

8Stabilizers, Blockers, & Substrates
CategoryIVD Reagents
Description

Stabilizers, blockers, and substrates used to optimize assay performance, improve shelf-life, and enhance detection sensitivity in diagnostic tests.

9Immuno-affinity Columns (IAC)
CategoryIVD Reagents
Description

Immuno-affinity columns (IAC) for sample purification and analyte isolation in diagnostic testing workflows.

10Polystreptavidin
CategoryIVD Reagents
Description

Polystreptavidin reagents for enhanced binding in diagnostic assays, particularly useful in lateral flow and ELISA applications.

11ELISA Kits
CategoryDiagnostic Test Kits
Description

ELISA kits for human diagnostic applications, covering autoimmune, infectious disease, and allergy testing.

12Transferrin (Holo & Apo)
CategoryCell Culture Reagents
Description

Transferrin products including iron-saturated Holo transferrin (near 100% saturation) and iron-poor Apo transferrin (near zero iron), produced in 5 kg ISO 13485 lots from FDA-screened plasma with heat pasteurization to WHO guidelines, for serum-free cell culture applications.

13Antibody Development
CategoryContract Services
Description

Goal-driven antibody development services including antigen mapping, hybridoma generation, and purified discovery antibody delivery within tight timelines, with rigorous screening and subcloning for IVD manufacturers.

14Antibody Manufacturing
CategoryContract Services
Description

Antibody production scaling up to 5g using roller-bottle or hollow-fibre bioreactors, with purification, polishing, conjugation, and characterization services under ISO 13485 certification.

15Lateral Flow Contract Manufacture
CategoryContract Manufacturing
Description

ISO 13485-certified lateral flow contract manufacturing including automated striping, laminating, cutting, and assembly of test devices from pilot lots to multi-million unit production runs.

16Custom Gold Conjugation
CategoryContract Services
Description

Custom gold conjugation services performing over 600 custom conjugations annually, linking antibodies, antigens, or oligos to ultra-uniform nanoparticles (≤8% CV) and scaling batches to 24L at OD10.

17Protein Customization
CategoryContract Services
Description

Protein customization services including gene screening, fermentation fine-tuning from pilot to production scale (up to 5,000L batches), and purification for bespoke antigens and high-activity enzymes.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Strategic partnership combining Lateral Dx's advanced assay development capabilities with BBI's ISO 13485-certified scalable manufacturing infrastructure. Enables customers to move from concept to commercial-scale production with reduced development timelines. Lateral Dx leads assay design and optimization; BBI provides end-to-end manufacturing and regulatory support from Crumlin facilities.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Major supplier of antibodies and reagents for research and diagnostic applications. Closely comparable to BBI's antibody and reagent catalog serving diagnostic assay developers, with similar B2B commercial model.

TypeBroad incumbent
Description

Global provider of bioprocessing and life sciences reagents including cell culture media and diagnostics components. Comparable to BBI in cell culture reagents (transferrin) and broader diagnostic raw materials supply.

TypeBroad incumbent
Description

Largest life sciences tools company, supplying enzymes, antibodies, and IVD raw materials. Competes broadly with BBI across reagent categories while also bundling instruments, consumables, and services.

TypeEmerging player
Description

Biotechnology company offering gene synthesis, protein production, and antibody development services. Comparable to BBI's antibody development and protein customization services for diagnostics and research customers.

TypeDirect peer
Description

Provider of clinical chemistry reagents, coagulation, and immunoassay components to IVD manufacturers. Direct overlap with BBI's clinical chemistry and immunoassay reagent business for the same diagnostic OEM customers.

TypeBroad incumbent
Description

Diversified life sciences tools company offering antibodies, proteins, ELISA kits, and reagents. Overlaps with BBI's antibody, antigen, and diagnostic reagent portfolio while operating at much greater scale across multiple end markets.

TypeDirect peer
Description

A leading manufacturer of diagnostic raw materials including antigens, antibodies, and reagents for IVD manufacturers. Directly comparable to BBI's core reagent catalog and lateral flow components business, serving the same IVD customer base.

TypeDirect peer
Description

Provider of IVD reagents and surface coatings for diagnostic test manufacturers. Comparable to BBI in serving IVD developers with critical reagents and immunoassay components, particularly in lateral flow and clinical chemistry.

TypeBroad incumbent
Description

Global life sciences tools and reagents giant offering antibodies, enzymes, and assay components. Competes with BBI across catalog reagent categories while also serving broader research and bioprocessing markets.

TypeEmerging player
Description

Asian-headquartered IVD raw materials supplier offering antigens, antibodies, and enzymes for diagnostic manufacturers. Increasingly competitive with BBI in gold conjugates and lateral flow components, particularly in APAC markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BBI Solutions

In Vitro Diagnostics (IVD) Reagentsbbisolutions.com

BBI Solutions manufactures IVD raw materials and contract manufacturing services — enzymes, antibodies, antigens, gold conjugates, and lateral flow components — for diagnostic OEMs and life sciences companies across five continents.

What BBI Solutions does

BBI Solutions is a UK-headquartered manufacturer of raw materials, reagents, and contract manufacturing services for the in vitro diagnostics (IVD) and life sciences industries. Founded in 1955 and operating from Crumlin with regional offices in Germany, the United States, China, and South Africa, the company employs over 500 people across seven global facilities. Its product portfolio centers on critical assay components: native and recombinant enzymes (including horseradish peroxidase, where BBI claims the position of world's largest primary manufacturer powering more than 5 billion glucose strips annually), antibodies, antigens, gold colloid and gold conjugates (powering more than 400 million lateral flow tests per year), cell culture reagents such as Holo and Apo transferrin, and human serum controls.

The company's core technology is upstream biochemical manufacturing rather than software or instrumentation. Production capabilities include up to 5,000-liter batch purification, gold nanoparticles with coefficient of variation of 8% or less, and over 600 custom gold conjugations per year, all operated under ISO 13485-certified quality systems with a supply resilience framework that includes inventory coverage and secondary sourcing for strategic products. Beyond catalog reagent sales, BBI operates a meaningful contract manufacturing business spanning antibody development and production, lateral flow device assembly from pilot to multi-million-unit runs, custom gold conjugation, and protein customization with fermentation fine-tuning.

BBI's commercial model is B2B sales-led, targeting IVD manufacturers and life sciences companies through direct enterprise sales, regional offices, an e-commerce storefront, and event marketing at industry conferences such as ADLM and ADA. Pricing is quotation-based, reflecting the customized nature of reagent supply and contract manufacturing agreements. The company is privately held under Baduhenna Topco Limited, has executed multiple acquisitions (including IBEX Technologies for $37.9 million in April 2024), and most recently announced a strategic partnership with Lateral Dx in December 2025 to integrate assay development with manufacturing scale.

BBI Solutions firmographics

Firmographics
Name
BBI Solutions
Legal name
Baduhenna Topco Limited
Website
https://bbisolutions.com
Company type
Private
Founded year
1986
Operating status
Operating
Headcount range
251–500 employees
Short description
BBI Solutions manufactures IVD raw materials and contract manufacturing services — enzymes, antibodies, antigens, gold conjugates, and lateral flow components — for diagnostic OEMs and life sciences companies across five continents.
Ownership category
akta.pro rank

BBI Solutions industry classification

Industry
Product category
In Vitro Diagnostics (IVD) Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro primary industry
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
akta.pro secondary industries
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

Keywords

  • IVD reagents
  • Diagnostic enzymes
  • Gold nanoparticles
  • Lateral flow assays
  • Antibody manufacturing

Where BBI Solutions is headquartered

Location

Headquarters

HQ city
Crumlin
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

BBI Solutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Reagent Product Sales: Sale of native and recombinant reagents including enzymes, antibodies, antigens, gold colloid, gold conjugates, cell culture reagents, stabilizers, blockers, and substrates to IVD manufacturers
  2. Contract Manufacturing Services: ISO 13485-certified manufacturing services including antibody production, lateral flow contract manufacture, and custom gold conjugation
  3. Custom Development: Tailored reagent customization including bespoke antigens, high-activity enzymes, protein customization, and custom conjugations

Pricing tiers

ModelBillingPrice
Other—B2B reagent sales with quotation-based pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

BBI Solutions product offering

Product offering

Core offering

BBI Solutions manufactures and supplies native and recombinant reagents for the in vitro diagnostics industry, including enzymes (notably Horseradish Peroxidase), antibodies, antigens, gold colloid, gold conjugates, cell culture reagents, human serum and control materials, immuno-affinity columns, polystreptavidin, stabilizers/blockers/substrates, and ELISA kits. The company complements its catalog with ISO 13485-certified contract manufacturing services covering antibody development and production, lateral flow device assembly, custom gold conjugation, and protein customization for diagnostic test developers.

Product overview

BBI Solutions is a provider of world-class reagents and IVD manufacturing services for the diagnostics and life sciences industries. The product portfolio centers on critical raw materials for diagnostic assay development: native and recombinant enzymes (including HRP, where BBI is the world's largest primary manufacturer powering over 5 billion annual glucose strips), antibodies and antigens across clinical areas (autoimmune, cardiac, infectious disease, diabetes, hormones, tumor markers), gold colloid and gold conjugates for lateral flow detection (powering 400+ million annual tests), cell culture reagents including transferrin products, and human serum control materials. The company complements its reagent catalog with contract manufacturing services including antibody development and production, lateral flow contract manufacture, custom gold conjugation (600+ annually), and protein customization. The portfolio is organized as catalog reagents plus customization services, supporting customers from discovery through commercial-scale production under ISO 13485 certification.

Differentiator

Problem solved

Functional benefit

Products and services

  • Enzymes Enzymes used as critical reagents in diagnostic testing, including Horseradish Peroxidase (HRP) where BBI is the world's largest primary manufacturer. Enzymes support applications such as glucose monitoring and lateral flow tests for IVD manufacturers.
  • Antibodies Antibodies for diagnostic assay development, including secondary antibodies and controls, used in IVD applications across autoimmune, inflammation, cardiac, and infectious diseases clinical areas.
  • Gold Colloid Gold colloid nanoparticles used as detection reagents in lateral flow diagnostics, with BBI's gold colloid powering over 400 million lateral flow tests annually.
  • Gold Conjugates Gold conjugate reagents linking antibodies, antigens, or oligos to ultra-uniform gold nanoparticles (≤8% CV) for lateral flow assay detection, with custom conjugation services available.
  • Antigens Antigens used as capture and detection reagents in immunoassays, covering clinical areas including infectious disease, tumor markers, hormones, and autoimmune conditions.
  • Cell Culture Reagents Cell culture reagents including Holo and Apo transferrin products manufactured under ISO 13485 certification from FDA-licensed plasma, used to accelerate cell growth in serum-free cultures.
  • Human Serum & Control Materials Human serum and control materials used as reference standards and quality controls in diagnostic assay development and manufacturing.
  • Stabilizers, Blockers, & Substrates Stabilizers, blockers, and substrates used to optimize assay performance, improve shelf-life, and enhance detection sensitivity in diagnostic tests.
  • Immuno-affinity Columns (IAC) Immuno-affinity columns (IAC) for sample purification and analyte isolation in diagnostic testing workflows.
  • Polystreptavidin Polystreptavidin reagents for enhanced binding in diagnostic assays, particularly useful in lateral flow and ELISA applications.
  • ELISA Kits ELISA kits for human diagnostic applications, covering autoimmune, infectious disease, and allergy testing.
  • Transferrin (Holo & Apo) Transferrin products including iron-saturated Holo transferrin (near 100% saturation) and iron-poor Apo transferrin (near zero iron), produced in 5 kg ISO 13485 lots from FDA-screened plasma with heat pasteurization to WHO guidelines, for serum-free cell culture applications.
  • Antibody Development Goal-driven antibody development services including antigen mapping, hybridoma generation, and purified discovery antibody delivery within tight timelines, with rigorous screening and subcloning for IVD manufacturers.
  • Antibody Manufacturing Antibody production scaling up to 5g using roller-bottle or hollow-fibre bioreactors, with purification, polishing, conjugation, and characterization services under ISO 13485 certification.
  • Lateral Flow Contract Manufacture ISO 13485-certified lateral flow contract manufacturing including automated striping, laminating, cutting, and assembly of test devices from pilot lots to multi-million unit production runs.
  • Custom Gold Conjugation Custom gold conjugation services performing over 600 custom conjugations annually, linking antibodies, antigens, or oligos to ultra-uniform nanoparticles (≤8% CV) and scaling batches to 24L at OD10.
  • Protein Customization Protein customization services including gene screening, fermentation fine-tuning from pilot to production scale (up to 5,000L batches), and purification for bespoke antigens and high-activity enzymes.

Quantifiable outcome

  • 5bn+ annual glucose strips powered by BBI enzymes
  • +4 more outcomes

Companies that use BBI Solutions

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

BBI Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BBI Solutions partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lateral DxcoreStrategic or Co-development Partner · 18 December 2025Strategic partnership combining Lateral Dx's advanced assay development capabilities with BBI's ISO 13485-certified scalable manufacturing infrastructure. Enables customers to move from concept to commercial-scale production with reduced development timelines. Lateral Dx leads assay design and optimization; BBI provides end-to-end manufacturing and regulatory support from Crumlin facilities.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

BBI Solutions competitors and assessment

Company assessment

Direct peers

  • Abcam: Major supplier of antibodies and reagents for research and diagnostic applications. Closely comparable to BBI's antibody and reagent catalog serving diagnostic assay developers, with similar B2B commercial model.
  • Sekisui Diagnostics: Provider of clinical chemistry reagents, coagulation, and immunoassay components to IVD manufacturers. Direct overlap with BBI's clinical chemistry and immunoassay reagent business for the same diagnostic OEM customers.
  • Meridian Bioscience (Revvity): A leading manufacturer of diagnostic raw materials including antigens, antibodies, and reagents for IVD manufacturers. Directly comparable to BBI's core reagent catalog and lateral flow components business, serving the same IVD customer base.
  • Surmodics: Provider of IVD reagents and surface coatings for diagnostic test manufacturers. Comparable to BBI in serving IVD developers with critical reagents and immunoassay components, particularly in lateral flow and clinical chemistry.

Broad incumbents

  • Cytiva (Danaher): Global provider of bioprocessing and life sciences reagents including cell culture media and diagnostics components. Comparable to BBI in cell culture reagents (transferrin) and broader diagnostic raw materials supply.
  • Thermo Fisher Scientific: Largest life sciences tools company, supplying enzymes, antibodies, and IVD raw materials. Competes broadly with BBI across reagent categories while also bundling instruments, consumables, and services.
  • Bio-Techne: Diversified life sciences tools company offering antibodies, proteins, ELISA kits, and reagents. Overlaps with BBI's antibody, antigen, and diagnostic reagent portfolio while operating at much greater scale across multiple end markets.
  • Merck KGaA / MilliporeSigma: Global life sciences tools and reagents giant offering antibodies, enzymes, and assay components. Competes with BBI across catalog reagent categories while also serving broader research and bioprocessing markets.

Emerging players

  • GenScript: Biotechnology company offering gene synthesis, protein production, and antibody development services. Comparable to BBI's antibody development and protein customization services for diagnostics and research customers.
  • Fapon Biotech: Asian-headquartered IVD raw materials supplier offering antigens, antibodies, and enzymes for diagnostic manufacturers. Increasingly competitive with BBI in gold conjugates and lateral flow components, particularly in APAC markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BBI Solutions social profiles

Digital presence

BBI Solutions compliance and trust

Trust signal

Compliance4 records

BBI Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BBI Solutions leadership team

Management profile

Number of profiles

Profiles3 records

BBI Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

BBI Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BBI Solutions M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BBI Solutions

What does BBI Solutions do?

BBI Solutions manufactures and supplies native and recombinant reagents for the in vitro diagnostics industry, including enzymes (notably Horseradish Peroxidase), antibodies, antigens, gold colloid, gold conjugates, cell culture reagents, human serum and control materials, immuno-affinity columns, polystreptavidin, stabilizers/blockers/substrates, and ELISA kits. The company complements its catalog with ISO 13485-certified contract manufacturing services covering antibody development and production, lateral flow device assembly, custom gold conjugation, and protein customization for diagnostic test developers.

Is BBI Solutions a public or private company?

BBI Solutions is a private company. It is classified as unknown and is currently operating.

When was BBI Solutions founded?

BBI Solutions was founded in 1986. It employs 251 to 500 people.

Where is BBI Solutions based?

BBI Solutions is headquartered in Crumlin, United Kingdom, in the Europe region.

How does BBI Solutions make money?

Three revenue lines are on record. Reagent Product Sales are the primary driver. The others are contract Manufacturing Services and custom Development.

Who are BBI Solutions's main competitors?

Direct peers on record are Abcam, Sekisui Diagnostics, Meridian Bioscience (Revvity) and Surmodics. Broad incumbents are Cytiva (Danaher), Thermo Fisher Scientific, Bio-Techne and Merck KGaA / MilliporeSigma. Emerging players are GenScript and Fapon Biotech.

Does BBI Solutions have an API?

No public API is recorded for BBI Solutions.

What industry is BBI Solutions in?

BBI Solutions's product category is In Vitro Diagnostics (IVD) Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireIBEX Completes Sale of the CompanyIBEX Technologies Inc. completed the sale of its company by amalgamating with BBI Solutions OEM Limited, acquiring all outstanding shares at $1.45 per share for a total consideration of approximately $37.9 million. The transaction was approved by shareholders on April 3, 2024, and IBEX has applied for delisting from the TSX Venture Exchange. BBI Solutions OEM Limited is an international provider of immunoassay products and services to the global diagnostics and life sciences industries.IbexBBI SolutionsBBI Solutions is a global manufacturer of specialist enzymes used in diagnostics, molecular biology, and life sciences research. The company operates ISO 13485-certified production facilities in the UK and South Africa, supplying products such as horseradish peroxidase and glucose oxidase to clients worldwide.BioSpaceIBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per ShareIBEX Technologies Inc. has entered into a binding acquisition agreement to be acquired by BBI Solutions OEM Limited through its subsidiary for $1.45 per share in cash, representing a total consideration of approximately $37.9 million. The transaction involves an amalgamation under the Canada Business Corporations Act and requires shareholder approval at a meeting scheduled for April 3, 2024. Key stakeholders holding nearly half of IBEX's shares have already agreed to support the deal, which is expected to result in IBEX delisting from the TSX Venture Exchange upon completion.GlobeNewswireIBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per ShareIBEX Technologies Inc. has entered into a definitive agreement to be acquired by BBI Solutions OEM Limited through its subsidiary, 15720273 Canada Inc., for $1.45 per share in cash, totaling approximately $37.9 million. The transaction involves an amalgamation under the Canada Business Corporations Act and includes a significant premium over IBEX's recent trading prices. The deal is subject to shareholder approval at a meeting scheduled for April 3, 2024, as well as regulatory approvals.PR NewswireGlobal Trypsin Market to Grow US$ 57.71 Million by 2028, Says Coherent Market InsightsAccording to Coherent Market Insights, the global trypsin market is valued at US$ 42.95 million in 2021 and is projected to reach US$ 57.71 million by 2028, growing at a CAGR of 4.3% during the forecast period (2021-2028). Key market trends include facility expansions and inorganic growth strategies such as acquisitions and collaborations among major players. Promega Corporation opened its Kornberg Center R&D facility in Fitchburg, U.S. in April 2021, while BBI Solutions completed the acquisition of DIARECT AG in June 2020 to expand its diagnostic reagent portfolio.GlobeNewswireAbingdon Health Notes Announcement by UK-RTC on providing an Antibody Certificate using smartphone App technologyUK-RTC announced that Abingdon Health's AbC-19 rapid test is now paired with a mobile app to generate antibody certificates on smartphones. The certificate is stored in the phone's wallet, requiring no new app installation. The solution was developed by BBI Solutions using Novarum technology.PR NewswireGlobal Proteinase K Market Analysis Report 2020-2027: Sudden Spike in COVID-19 Cases Presents OpportunitiesThe global Proteinase K market is projected to reach US$ 107.5 million by 2027, driven by increasing COVID-19 cases and growing demand for diagnostics and point-of-care testing. The infectious diseases segment held the largest revenue share in 2019, while North America led regional market share due to the spike in COVID-19 infections and presence of key manufacturers. Key players in the market include Merck KGaA, BBI Solutions, Codexis Inc., and F. Hoffmann-La Roche Ltd, among others listed in the report.